written on 26.02.2014

InterMune ASCENDs on new Phase III pirfenidone data


Brisbane, California-based InterMune's stock soared 170.8% higher on 25 February to close at $37.80 per share with a $3bn market cap after the company said pirfenidone cut the percentage of IPF patients who died or experienced a 10% decrease in lung…